RESUMO
The combination of a polyphenol, quercetin, with dasatinib initiated clinical trials to evaluate the safety and efficacy of senolytics in idiopathic pulmonary fibrosis, a lung disease associated with the presence of senescent cells. Another approach to senotherapeutics consists of controlling inflammation related to cellular senescence or "inflammaging", which participates, among other processes, in establishing pulmonary fibrosis. We evaluate whether polyphenols such as caffeic acid, chlorogenic acid, epicatechin, gallic acid, quercetin, or resveratrol combined with different senotherapeutics such as metformin or rapamycin, and antifibrotic drugs such as nintedanib or pirfenidone, could present beneficial actions in an in vitro model of senescent MRC-5 lung fibroblasts. A senescent-associated secretory phenotype (SASP) was evaluated by the measurement of interleukin (IL)-6, IL-8, and IL-1ß. The senescent-associated ß-galactosidase (SA-ß-gal) activity and cellular proliferation were assessed. Fibrosis was evaluated using a Picrosirius red assay and the gene expression of fibrosis-related genes. Epithelial-mesenchymal transition (EMT) was assayed in the A549 cell line exposed to Transforming Growth Factor (TGF)-ß in vitro. The combination that demonstrated the best results was metformin and caffeic acid, by inhibiting IL-6 and IL-8 in senescent MRC-5 cells. Metformin and caffeic acid also restore cellular proliferation and reduce SA-ß-gal activity during senescence induction. The collagen production by senescent MRC-5 cells was inhibited by epicatechin alone or combined with drugs. Epicatechin and nintedanib were able to control EMT in A549 cells. In conclusion, caffeic acid and epicatechin can potentially increase the effectiveness of senotherapeutic drugs in controlling lung diseases whose pathophysiological component is the presence of senescent cells and fibrosis.
Assuntos
Senescência Celular , Fibroblastos , Pulmão , Polifenóis , Humanos , Fibroblastos/efeitos dos fármacos , Fibroblastos/metabolismo , Senescência Celular/efeitos dos fármacos , Polifenóis/farmacologia , Pulmão/patologia , Pulmão/efeitos dos fármacos , Pulmão/metabolismo , Células A549 , Proliferação de Células/efeitos dos fármacos , Transição Epitelial-Mesenquimal/efeitos dos fármacos , Metformina/farmacologia , Ácidos Cafeicos/farmacologia , Indóis/farmacologia , Senoterapia/farmacologia , Linhagem Celular , Fenótipo Secretor Associado à Senescência/efeitos dos fármacos , Sirolimo/farmacologia , Interleucina-8/metabolismo , Interleucina-8/genética , Fator de Crescimento Transformador beta/metabolismo , PiridonasRESUMO
BACKGROUND: The global need for palliative care (PC) is increasing, especially as the population ages. The diagnosis of a life-threatening illness triggers numerous decisions by healthcare professionals (HCPs). How these professionals understand and deal with PC influences the quantity and quality of care provided to patients. This systematic review aimed to compare perceptions of PC among HCPs around the world. METHODS: The databases (MEDLINE/PubMed, Embase, LILACS, and EBSCO) were searched systematically. Articles reporting on the perception of HCPs, published between January 2012 and December 2022, were included. Texts that reported the perceptions of family members and patients were excluded to avoid the risk of bias. Those included were organized by country/region and continent for later analysis. RESULTS: Of the 2,063 articles initially retrieved 32 were included and provided relevant information from four continents (America, Asia, Europe, and Oceania). Most of this was done through interviews and questionnaires. All HCPs consulted in the studies recognized the importance of PC. The perception of these professionals was influenced by cultural factors (such as religion), difficulties perceived in each country/region (such as inadequate knowledge, conceptual confusion, etc.), diseases, and the age range of patients served. The acceptance and preparation of professionals to deal with this topic in their routine also influenced their perceptions of HCPs. The limitation of this research is the lack of eligible studies from Africa and the small number of participants in some studies. CONCLUSIONS: It can be concluded that HCPs' perceptions of PC are similar, regardless of their country of origin.
Assuntos
Atitude do Pessoal de Saúde , Cuidados Paliativos , Humanos , Cuidados Paliativos/psicologia , Europa (Continente) , Pessoal de Saúde/psicologia , Ásia , Oceania , AméricaRESUMO
Objective: Evaluate the effectiveness of resveratrol as a hepatoprotector in a rat model of paracetamol-induced liver injury and its biodistribution to understand its pharmacokinetics. Methodology: As an experimental approach, animals were divided into the test group with 4 subgroups and the control group with 4 subgroups. Animals of the "treated" group were subjected to resveratrol pre-treatment for eight days, followed by intoxication with a high dose of paracetamol on the 8th day. Animals were euthanized to collect the blood and liver tissue samples 24 and 72 h after the last administration. Hepatoprotective activity was evaluated through serum levels of glycogen and hepatic enzymes, such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP), histological and morphometric analysis of the liver tissue. For biodistribution analysis, different organs (organs, kidneys, heart and lungs) were collected and macerated, and resveratrol was quantified using high-performance liquid chromatography. Statistical analyses of morphometry, transaminases and alkaline phosphatase measurements, and biodistribution results were performed using GraphPad Prism® 3.0. Differences between groups were compared using ANOVA, followed by the Bonferroni test. Statistical significance was set at p < 0.05. Results: Resveratrol has a hepatoprotective action against acute intoxication by paracetamol, as evidenced by the histological decrease in necrosis and inflammatory foci, preservation of glycogen and other 1,2-glycols in zone 3, and reduction of serum ALT and AST levels. An increased presence of collagen was observed in acinar zones 1 and 3 with picrosirius red staining; therefore, quantification was performed in these regions showing smaller collagen areas in the R and RP groups than in the PC and NC groups Paracetamol caused a significant reduction in the resveratrol concentration in serum and the organs studied, indicating that the antioxidant activity of resveratrol is related to its hepatoprotective action. Conclusion: Resveratrol has hepatoprotective properties and can mitigate some of the liver damage caused by high doses of paracetamol, as indicated by changes in tissue characteristics and liver enzyme levels.
Objetivo: Avaliar a eficácia do resveratrol como hepatoprotetor em modelo de rato com lesão hepática induzida por paracetamol e sua biodistribuição para compreender sua farmacocinética. Metodologia: Como abordagem experimental, os animais foram divididos em grupo teste com 4 subgrupos e grupo controle com 4 subgrupos. Os animais do grupo "tratado" foram submetidos ao pré-tratamento com resveratrol durante oito dias, seguido de intoxicação com alta dose de paracetamol no oitavo dia. Os animais foram eutanasiados para coleta de amostras de sangue e tecido hepático 24 e 72 horas após a última administração. A atividade hepatoprotetora foi avaliada através dos níveis séricos de glicogênio e de enzimas hepáticas, como aspartato aminotransferase (AST), alanina aminotransferase (ALT) e fosfatase alcalina (ALP), análise histológica e morfométrica do tecido hepático. Para análise de biodistribuição, diferentes órgãos (órgãos, rins, coração e pulmões) foram coletados e macerados, e o resveratrol foi quantificado por cromatografia líquida de alta eficiência. Análises estatísticas de morfometria, medidas de transaminases e fosfatase alcalina e resultados de biodistribuição foram realizadas utilizando GraphPad Prism® 3.0. As diferenças entre os grupos foram comparadas por meio de ANOVA, seguida do teste de Bonferroni. A significância estatística foi estabelecida em p < 0,05. Resultados: O resveratrol tem ação hepatoprotetora contra a intoxicação aguda por paracetamol, evidenciada pela diminuição histológica da necrose e dos focos inflamatórios, preservação do glicogênio e outros 1,2-glicóis na zona 3 e redução dos níveis séricos de ALT e AST. Foi observada presença aumentada de colágeno nas zonas acinares 1 e 3 com coloração picrosirius red; portanto, foi realizada quantificação nessas regiões mostrando menores áreas de colágeno nos grupos tratados com resveratrol e resveratrol associado com paracetamol do que nos grupos controles positivo e negativo. O paracetamol causou redução significativa na concentração de resveratrol no soro e nos órgãos estudados, indicando que a atividade antioxidante do resveratrol está relacionada à sua ação hepatoprotetora. Conclusão: O resveratrol possui propriedades hepatoprotetoras e pode mitigar alguns dos danos hepáticos causados por altas doses de paracetamol, conforme indicado por alterações nas características dos tecidos e nos níveis de enzimas hepáticas.
Assuntos
Animais , Resveratrol , Farmacocinética , Medicamentos Hepatoprotetores , AcetaminofenRESUMO
Objectives: the aim of this study was to evaluate the effects of the association of dry extracts of Astragalus membranaceus, Peumus boldus and Curcuma longa in rats with induced diabetes. Methods: After the induction of type 2 diabetes by intraperitoneal streptozotocin, male Wistar rats were randomly assigned to groups (n=6) and treated for 20 days. The extracts were suspended in water and administered through orogastric gavage once daily as described: Group I: healthy control (saline); group II: received Astragalus membranaceus, Peumus boldus and Curcuma longa (400 mg/kg/day of each dry extract); group III: received Astragalus membranaceus, Peumus boldus, Curcuma longa (400 mg/kg/day of each dry extract) and glibenclamide (15 mg/kg/day). Fasting glucose, glucose tolerance, alanine aminotransferase, aspartate aminotransferase and fructosamine were evaluated. Results: Fasting blood glucose and glucose tolerance for groups II and III were influenced by treatments (p<0.05). The extracts did not significantly influence the efficacy of glibenclamide. Conclusion: The results found in this study allow us to consider that it is not possible to conclude that the compounds evaluated are not effective in DM in rats, due to variables such as total treatment period, doses, size of pancreatic injury caused by streptozotocin, and diet profile may have influenced the results. The studied compounds have potential for application in diabetes and further studies should be carried out to adjust the treatment.
Objetivos: avaliar os efeitos da associação de extratos secos de Astragalus membranaceus, Peumus boldus e Curcuma longa em ratos com diabetes induzida. Métodos: Após a indução de diabetes tipo 2 (DM) por estreptozotocina intraperitoneal, ratos Wistar machos foram distribuídos aleatoriamente em grupos (n=6) e tratados por 20 dias. Os extratos foram suspensos em água e administrados por gavagem orogástrica uma vez ao dia conforme descrito: Grupo I: controle saudável (solução salina); grupo II: recebeu Astragalus membranaceus, Peumus boldus e Curcuma longa (400 mg/kg/dia de cada extrato seco); grupo III: receberam Astragalus membranaceus, Peumus boldus, Curcuma longa (400 mg/kg/dia de cada extrato seco) e glibenclamida (15 mg/kg/dia). A glicemia de jejum, tolerância à glicose, alanina aminotransferase, aspartato aminotransferase e frutosamina foram avaliados. Resultados: A glicemia de jejum e a tolerância à glicose para os grupos II e III foram influenciadas pelos tratamentos (p<0,05). Os extratos não influenciaram significativamente na eficácia da glibenclamida. Conclusão: Os resultados encontrados neste estudo permitem considerar que não é possível concluir que os compostos avaliados não são eficazes no DM em ratos, devido às variáveis como tempo total de tratamento, doses e tamanho da lesão pancreática causada por estreptozotocina, além do perfil da dieta, que podem ter influenciado os resultados. Os compostos estudados têm potencial para aplicação em diabetes e mais estudos devem ser realizados para adequar o tratamento.
Assuntos
Astragalus propinquus , Glicemia , Estreptozocina , Frutosamina , Curcuma , Peumus , Diabetes Mellitus , Alanina TransaminaseRESUMO
ABSTRACT Objective: To characterize the self-reported adherence of patients with cardiovascular diseases to the use of new oral anticoagulants and to identify factors related to adherence to these drugs. Method: This is a descriptive, correlational, and cross-sectional study, carried out with outpatients. The collection of sociodemographic, clinical, and adherence data, through the Measurement of Adherence to Treatments, was made through telephone calls. Descriptive, correlation, and multiple linear regression analyses were used. Results: A total of 120 patients using new anticoagulants for 32.3 months, on average, participated in the study. More than half of the sample consisted of women, who were professionally inactive, with a mean age of 70.1 years and a mean family income of 6.7 minimum wages. The mean adherence score was 5.7, in a possible range between 1 and 6, indicating medication adherence. Inactive employment status, female sex, higher family income, and follow-up at a public outpatient clinic were related to greater adherence to these medications. Conclusion: The patients showed high adherence to new anticoagulants. Employment status, sex, family income, and type of outpatient follow-up were related to medication adherence, and should be considered in the design of interventions for this public.
RESUMEN Objetivo: caracterizar la adhesión autorrelatada de los pacientes con enfermedades cardiovasculares al uso de nuevos anticoagulantes orales e identificar los factores relacionados a la adhesión a esos medicamentos. Método: estudio descriptivo, correlacional y transversal, con paciente ingresado. La recolección de datos sociodemográficos, clínicos y de adhesión, por medio de la Medida de Adhesión a los Tratamientos, ocurrió a través del teléfono. Se utilizaron el análisis descriptivo, correlacional y de regresión lineal múltiple. Resultados: participaron del estudio 120 pacientes que utilizaron nuevos anticoagulantes por 32,3 meses, aproximadamente. Más de la mitad de la muestra estuvo compuesta de mujeres jubiladas, con edad promedia de 70,1 años y remuneración familiar promedia de 6,7 sueldos mínimos. El score promedio de adhesión fue de 5,7, dentro de un período posible entre 1 y 6, lo que indicó adhesión farmacológica. Conclusión: los pacientes presentaron elevada adhesión a los nuevos anticoagulantes. Situación laboral, sexo, renta familiar y tipo de acompañamiento en ambulatorio estuvieron relacionados a la adhesión farmacológica, debiendo ser considerados en la delineación de intervenciones para ese público.
Assuntos
Enfermagem , Adesão à Medicação , AnticoagulantesRESUMO
OBJECTIVE: To characterize the self-reported adherence of patients with cardiovascular diseases to the use of new oral anticoagulants and to identify factors related to adherence to these drugs. METHOD: This is a descriptive, correlational, and cross-sectional study, carried out with outpatients. The collection of sociodemographic, clinical, and adherence data, through the Measurement of Adherence to Treatments, was made through telephone calls. Descriptive, correlation, and multiple linear regression analyses were used. RESULTS: A total of 120 patients using new anticoagulants for 32.3 months, on average, participated in the study. More than half of the sample consisted of women, who were professionally inactive, with a mean age of 70.1 years and a mean family income of 6.7 minimum wages. The mean adherence score was 5.7, in a possible range between 1 and 6, indicating medication adherence. Inactive employment status, female sex, higher family income, and follow-up at a public outpatient clinic were related to greater adherence to these medications. CONCLUSION: The patients showed high adherence to new anticoagulants. Employment status, sex, family income, and type of outpatient follow-up were related to medication adherence, and should be considered in the design of interventions for this public.
Assuntos
Anticoagulantes , Doenças Cardiovasculares , Idoso , Estudos Transversais , Feminino , Humanos , Adesão à Medicação , AutorrelatoRESUMO
BACKGROUND: Rutin is a flavonol glycoside that can be found in a wide variety of vegetables and has activity, anti-cancer, anti-inflammatory and anti-diabetic properties. OBJECTIVE: This study investigated the effect of rutin oral administration on Wistar rats submitted to hepatic hyperplasia after partial hepatectomy (PH). METHODS: To achieve this, we considered the analysis of hepatic hyperplastic and plasma biochemical activity of Wistar rats, subjected to treatment with rutin 40 mg/kg/day for 10 days in group 1 (G1) or saline in group 2 (G2), followed by partial hepatectomy. RESULTS: The results indicated an increase in the number of mitoses after 24 hours and 48 hours (P=0.0022 and P=0.0152, respectively) of PH in the group that received rutin, as well as an increase in AST serum levels after 24 hours (P=0.0159) and 48 hours (P=0.0158) and alkaline phosphatase after 24 hours (P=0.015) in the same group, in relation to the respective controls. The group that received rutin showed a more evident variation than the control group when comparing the 24 hour and 48 hour results regarding AST, number of mitoses and number of apoptosis (P<0.005). CONCLUSION: It was concluded that rutin intervened in hepatic hyperplasia after 24 hours and 48 hours of PH, favoring hepatic hyperplasia.
Assuntos
Hiperplasia , Rutina , Alanina Transaminase , Animais , Aspartato Aminotransferases , Ratos , Ratos WistarRESUMO
ABSTRACT BACKGROUND: Rutin is a flavonol glycoside that can be found in a wide variety of vegetables and has activity, anti-cancer, anti-inflammatory and anti-diabetic properties. OBJECTIVE: This study investigated the effect of rutin oral administration on Wistar rats submitted to hepatic hyperplasia after partial hepatectomy (PH). METHODS: To achieve this, we considered the analysis of hepatic hyperplastic and plasma biochemical activity of Wistar rats, subjected to treatment with rutin 40 mg/kg/day for 10 days in group 1 (G1) or saline in group 2 (G2), followed by partial hepatectomy. RESULTS: The results indicated an increase in the number of mitoses after 24 hours and 48 hours (P=0.0022 and P=0.0152, respectively) of PH in the group that received rutin, as well as an increase in AST serum levels after 24 hours (P=0.0159) and 48 hours (P=0.0158) and alkaline phosphatase after 24 hours (P=0.015) in the same group, in relation to the respective controls. The group that received rutin showed a more evident variation than the control group when comparing the 24 hour and 48 hour results regarding AST, number of mitoses and number of apoptosis (P<0.005). CONCLUSION: It was concluded that rutin intervened in hepatic hyperplasia after 24 hours and 48 hours of PH, favoring hepatic hyperplasia.
RESUMO CONTEXTO: A rutina é um flavonoide que pode ser encontrado em grande variedade de vegetais e apresenta atividades anticâncer, anti-inflamatória e antidiabética. OBJETIVO: O objetivo deste estudo foi investigar o efeito da administração oral de rutina sobre a hiperplasia hepática em ratos Wistar submetidos à hepatectomia parcial. MÉTODOS: Foi realizada a análise da hiperplasia hepática e da bioquímica plasmática dos ratos Wistar tratados com rutina 40 mg/kg por 10 dias no grupo 1 (G1) ou salina no grupo 2 (G2), seguido da hepatectomia parcial. RESULTADOS: Os resultados indicaram aumento do número de mitoses após 24 e 48 horas (P=0,0022 e P=0,0152, respectivamente) da hepatectomia parcial no grupo que recebeu rutina, além de um aumento nos níveis séricos de AST após 24 horas (P=0,0159) e 48 horas (P=0,0158) e de fosfatase alcalina após 24 horas (P=0,015) no mesmo grupo, em relação aos respectivos controles. O grupo que recebeu rutina mostrou variação mais evidente do que o grupo controle quando se comparou os resultados de 24 horas e 48 horas em relação a AST, número de mitoses e número de apoptoses (P<0,005). CONCLUSÃO: Foi possível concluir que a rutina interferiu na hiperplasia hepática após 24 e 48 horas após a hepatectomia parcial, favorecendo a hiperplasia hepática.
Assuntos
Animais , Ratos , Rutina , Hiperplasia , Aspartato Aminotransferases , Ratos Wistar , Alanina TransaminaseRESUMO
Purpose: Coleus forskohlii Briq., a medicinal plant originally from India, has been indicated against heart disease, expiratory disorders, convulsions, and hepatic changes, among others. In view of the broad pharmacological potential of the plant and the scarce information about its effects, the objective of the present study was to investigate the effect of its use for pretreatment of partially hepatectomized rats. Methods: The animals were divided into two experimental groups: Control (CG) receiving physiological saline for 10 days before partial hepatetctomy, and Treated (TG) receiving 40 mg Coleus forskohlii/kg/day for 10 days before partial hepatectomy. The treatments were performed by gastric gavage. After the surgical procedure, treatment was continued according to the following groups: CG 24 h, CG 48 h, TG 24 h, and TG 48 hs, and liver tissue and intracardiac blood samples were obtained for histological and biochemical analysis, respectively. Results: No significant differences were observed in mitotic or apoptotic index or in the concentrations of the enzymes AST, ALT and alkaline phosphatase, and no areas of fibrosis were detected. Conclusion: Treatment with Coleus forskohlii did not interfere with the course of hepatic hyperplasia.(AU)
Assuntos
Animais , Masculino , Ratos , Hepatopatias/tratamento farmacológico , Hepatopatias/prevenção & controle , Hiperplasia/tratamento farmacológico , Hiperplasia/prevenção & controle , Hepatectomia/métodos , Coleus/efeitos dos fármacos , Fígado/anatomia & histologia , Fígado/química , Plantas Medicinais/efeitos dos fármacos , Ratos Wistar/cirurgiaRESUMO
PURPOSE: Coleus forskohlii Briq., a medicinal plant originally from India, has been indicated against heart disease, expiratory disorders, convulsions, and hepatic changes, among others. In view of the broad pharmacological potential of the plant and the scarce information about its effects, the objective of the present study was to investigate the effect of its use for pretreatment of partially hepatectomized rats. METHODS: The animals were divided into two experimental groups: Control (CG) receiving physiological saline for 10 days before partial hepatetctomy, and Treated (TG) receiving 40 mg Coleus forskohlii/kg/day for 10 days before partial hepatectomy. The treatments were performed by gastric gavage. After the surgical procedure, treatment was continued according to the following groups: CG 24 h, CG 48 h, TG 24 h, and TG 48 hs, and liver tissue and intracardiac blood samples were obtained for histological and biochemical analysis, respectively. RESULTS: No significant differences were observed in mitotic or apoptotic index or in the concentrations of the enzymes AST, ALT and alkaline phosphatase, and no areas of fibrosis were detected. CONCLUSION: Treatment with Coleus forskohlii did not interfere with the course of hepatic hyperplasia.
Assuntos
Hepatectomia/métodos , Fígado/patologia , Extratos Vegetais/administração & dosagem , Plectranthus/química , Alanina Transaminase/sangue , Fosfatase Alcalina/sangue , Animais , Aspartato Aminotransferases/sangue , Biomarcadores/sangue , Hepatócitos/efeitos dos fármacos , Hiperplasia/tratamento farmacológico , Fígado/efeitos dos fármacos , Fígado/cirurgia , Masculino , RatosRESUMO
Objective This study aimed to extract the essential oil of Curcuma longa rhizomes collected in Brazil, determine its composition by gas chromatography and mass spectrometry, and evaluate its hemolytic action and antimicrobial activity. Methods The oil extraction was performed by hydrodistillation; its composition was determined by GC-MS; the Minimum Inhibitory Concentration was evaluated through microdilution, and the hemolytic activity was analyzed in sheep red blood cells. Results The essential oil's major components are zingiberene (11%), sesquiphellandrene (10%), ß-turmerone (10%), and α-curcumene (5%). It proved efficient at inhibiting Staphylococcus aureus with Minimum Inhibitory Concentrations of 38.8µl/mL, Staphylococcus epidermidis (Minimum Inhibitory Concentrations of 50.0µl/mL), Escherichia coli (Minimum Inhibitory Concentrations of 44.4µl/mL), and Pseudomonas aeruginosa (Minimum Inhibitory Concentrations of 27.7µl/mL). Conclusion Despite provoking hemolysis in sheep red blood cells, the essential oil suggests promising results for a variety of purposes due to its antibacterial properties. Supplementary research is necessary to determine in vivo activity and the potential use of the C. longa essential oil as an antimicrobial agent in diverse situations.
Objetivo Este trabalho teve como objetivo determinar a composição e avaliar as atividades antimicrobiana e hemolítica do óleo essencial de rizomas da Curcuma longa L. Métodos A extração do óleo essencial foi realizada por hidrodestilação e sua composição determinada por cromatografia gasosa com espectrometria de massas. A Concentração Mínima Inibitória foi avaliada por microdiluição e a atividade hemolítica foi analisada em hemácias de carneiro. Resultados Os componentes majoritários encontrados foram zingibereno (11%), sesquipelenadieno (10%), ß-turmerona (10%) e α-curcumeno (5%). O óleo essencial provocou hemólise e inibiu Staphylococcus aureus (Concentração Mínima Inibitória=38,8µl/mL), Staphylococcus epidermidis (Concentração Mínima Inibitória=50,0µl/mL), Escherichia coli (Concentração Mínima Inibitória=44,4µl µl/mL) e Pseudomonas aeruginosa (Concentração Mínima Inibitória=27,7µl/mL). Conclusão Apesar de provocar hemólise, o óleo essencial analisado tem potencial para diversas finalidades, devido às suas propriedades antibacterianas. Estudos complementares são necessários para determinar a atividade in vivo e o potencial uso de óleo essencial de C. longa como agente antimicrobiano em diversas situações.
Assuntos
Óleos Voláteis , Curcuma , Cromatografia Gasosa-Espectrometria de Massas , Anti-Infecciosos , HemóliseRESUMO
Abstract Purpose Coleus forskohlii Briq., a medicinal plant originally from India, has been indicated against heart disease, expiratory disorders, convulsions, and hepatic changes, among others. In view of the broad pharmacological potential of the plant and the scarce information about its effects, the objective of the present study was to investigate the effect of its use for pretreatment of partially hepatectomized rats. Methods The animals were divided into two experimental groups: Control (CG) receiving physiological saline for 10 days before partial hepatetctomy, and Treated (TG) receiving 40 mg Coleus forskohlii/kg/day for 10 days before partial hepatectomy. The treatments were performed by gastric gavage. After the surgical procedure, treatment was continued according to the following groups: CG 24 h, CG 48 h, TG 24 h, and TG 48 hs, and liver tissue and intracardiac blood samples were obtained for histological and biochemical analysis, respectively. Results No significant differences were observed in mitotic or apoptotic index or in the concentrations of the enzymes AST, ALT and alkaline phosphatase, and no areas of fibrosis were detected. Conclusion Treatment with Coleus forskohlii did not interfere with the course of hepatic hyperplasia.
Assuntos
Animais , Masculino , Ratos , Extratos Vegetais/administração & dosagem , Plectranthus/química , Hepatectomia/métodos , Fígado/patologia , Aspartato Aminotransferases/sangue , Biomarcadores/sangue , Hepatócitos/efeitos dos fármacos , Alanina Transaminase/sangue , Fosfatase Alcalina/sangue , Hiperplasia/tratamento farmacológico , Fígado/cirurgia , Fígado/efeitos dos fármacosRESUMO
PURPOSE: To investigate the effects of capsiate treatment on hepatic hyperplasia in partially hepatectomized rats. METHODS: The animals were divided into a Capsiate group (CPH), a Capsiate Post-Partial Hepatectomy group (CPPH) and a Partial Hepatectomy Control group (PH). CPH and CPPH animals received 60 mg/kg/day Capsiate for 30 days. Next, the rats underwent partial hepatectomy. CPPH animals continued to receive treatment for 48 h after partial hepatectomy. Liver tissue and intracardiac blood samples were obtained 24 or 48 h after PH. RESULTS: Capsiate treatment interfered with hepatic parameters, reducing the number of mitoses and apoptosis and increasing blood ALT and alkaline phosphatase concentrations. CONCLUSION: Capsiate treatment preceding hepatic surgery may compromise the initial period of postoperative recovery.
Assuntos
Capsaicina/análogos & derivados , Hepatectomia , Fígado/enzimologia , Alanina Transaminase/metabolismo , Fosfatase Alcalina/metabolismo , Animais , Apoptose/efeitos dos fármacos , Aspartato Aminotransferases/metabolismo , Capsaicina/farmacologia , Fígado/efeitos dos fármacos , Fígado/patologia , Regeneração Hepática/efeitos dos fármacos , Masculino , Mitose/efeitos dos fármacos , Ratos , Ratos WistarRESUMO
Abstract Purpose: To investigate the effects of capsiate treatment on hepatic hyperplasia in partially hepatectomized rats. Methods: The animals were divided into a Capsiate group (CPH), a Capsiate Post-Partial Hepatectomy group (CPPH) and a Partial Hepatectomy Control group (PH). CPH and CPPH animals received 60 mg/kg/day Capsiate for 30 days. Next, the rats underwent partial hepatectomy. CPPH animals continued to receive treatment for 48 h after partial hepatectomy. Liver tissue and intracardiac blood samples were obtained 24 or 48 h after PH. Results: Capsiate treatment interfered with hepatic parameters, reducing the number of mitoses and apoptosis and increasing blood ALT and alkaline phosphatase concentrations. Conclusion: Capsiate treatment preceding hepatic surgery may compromise the initial period of postoperative recovery.
Assuntos
Animais , Masculino , Ratos , Capsaicina/análogos & derivados , Hepatectomia , Fígado/enzimologia , Aspartato Aminotransferases/metabolismo , Capsaicina/farmacologia , Ratos Wistar , Apoptose/efeitos dos fármacos , Alanina Transaminase/metabolismo , Fosfatase Alcalina/metabolismo , Fígado/efeitos dos fármacos , Fígado/patologia , Regeneração Hepática/efeitos dos fármacos , Mitose/efeitos dos fármacosRESUMO
Purpose: To investigate the effects of capsiate treatment on hepatic hyperplasia in partially hepatectomized rats. Methods: The animals were divided into a Capsiate group (CPH), a Capsiate Post-Partial Hepatectomy group (CPPH) and a Partial Hepatectomy Control group (PH). CPH and CPPH animals received 60 mg/kg/day Capsiate for 30 days. Next, the rats underwent partial hepatectomy. CPPH animals continued to receive treatment for 48 h after partial hepatectomy. Liver tissue and intracardiac blood samples were obtained 24 or 48 h after PH. Results: Capsiate treatment interfered with hepatic parameters, reducing the number of mitoses and apoptosis and increasing blood ALT and alkaline phosphatase concentrations. Conclusion: Capsiate treatment preceding hepatic surgery may compromise the initial period of postoperative recovery.(AU)
Assuntos
Animais , Masculino , Ratos , Capsaicina/análogos & derivados , Capsaicina/efeitos adversos , Capsaicina/uso terapêutico , Hepatectomia/reabilitação , Período Pós-OperatórioRESUMO
ABSTRACT Objective To evaluate the protein quality and iron bioavailability of a fortifying mixture based on pork liver. Methods Determinations of protein efficiency ratio, net protein utilization, true digestibility and hemoglobin regeneration efficiency by depletion and repletion were performed. In the depletion phase, the animals (male Wistar rats) received an iron-free AIN-93G diet and in the repletion phase they received the following diets: standard AIN-93G diet, fortifying mixture and standard diet containing heptahydrated ferrous sulfate for comparison. Results For standard AIN-93G diet and fortifying mixture the results were 3.75 and 4.04 for protein efficiency ratio and 3.53 and 3.63 for net protein retention, showing that the presence of pork liver in the diet promoted an increase in protein efficiency ratio and net protein retention (not statistically significant). True digestibility results obtained with the fortifying mixture (97.16%) were higher than those obtained with the standard AIN-93G diet (casein), but without significant difference. The hemoglobin regeneration efficiency values obtained for standard AIN-93G diet, fortifying mixture and standard diet containing heptahydrated ferrous sulfate were 50.69, 31.96 and 29.96%, respectively, showing a statistically significant difference between the control (standard AIN-93G diet) and test (fortifying mixture and standard diet containing heptahydrated ferrous sulfate) samples, but not between the test samples. Conclusion The fortifying mixture showed a high protein efficiency ratio value of 4.04 and a high relative biological value (108%) and it can be added to soups, creams and meats in day-care centers for the prevention of iron-deficiency in children of school age.
RESUMO Objetivo Avaliar a qualidade protéica e a biodisponibilidade de ferro de uma mistura fortificadora a base de fígado suíno. Métodos Foram determinados coeficiente de eficácia protéica, retenção protéica líquida, digestibilidade verdadeira e de eficiência da regeneração de hemoglobina (depleção e repleção). Na fase de depleção os animais (ratos da linhagem Wistar) receberam dieta (AIN-93G) isenta de ferro e na fase de repleção receberam as dietas: padrão AIN-93G (dietas padrão AIN-93G), mistura fortificadora e dieta-padrão com sulfato ferroso heptahidratado para comparação. Resultados Para dietas padrão AIN-93G e mistura fortificadora os resultados foram respectivamente 3,75 e 4,04 para coeficiente de eficácia protéica e 3,53 e 3,63 para retenção protéica líquida mostrando que a presença de fígado suíno promoveu aumento dos valores de coeficiente de eficácia protéica e retenção protéica líquida (sem diferença estatística). Resultados de digestibilidade verdadeira obtidos com a dieta mistura fortificadora (97,16%) foram maiores do que os obtidos com a dietas padrão AIN-93G (caseína), também sem diferença estatística. Os resultados de eficiência da regeneração de hemoglobina para dietas padrão AIN-93G, mistura fortificadora e sulfato ferroso heptahidratado foram respectivamente 50,69; 31,96 e 29,96% apresentando diferença estatística significativa entre a amostra controle (dietas padrão AIN-93G) e as amostras testes (mistura fortificadora e sulfato ferroso heptahidratado), porém não entre as amostras testes. Conclusão A mistura fortificadora se mostrou com alto coeficiente de eficácia protéica (4,04) e alto valor biológico relativo (108%) podendo ser adicionada às sopas, cremes, carnes em creches na prevenção e controle da anemia ferropriva em crianças em idade escolar.
Assuntos
Animais , Ratos , Ferro , Proteínas , Alimentos Fortificados , Ratos Wistar , Micronutrientes , Dieta Rica em ProteínasRESUMO
PURPOSE:: To investigate the effects of lycopene and resveratrol pretreatment on hepatic hyperplasia in partially hepatectomized rats. METHODS:: The lycopene group and the resveratrol group received 40 mg/kg/day of lycopene or resveratrol, respectively (dissolved in olive oil or in saline solution, respectively) and administered via a gastric tube for 30 days. The partially hepatectomzed (PH) control groups received saline or olive oil via a gastric tube for 30 days, respectively, and the normal control group received no treatment. Liver tissue and intracardiac blood samples were obtained 24, 36 or 48 h after PH. RESULTS:: No areas of fibrosis were detected. No significant changes in mitotic index, in the number of apoptosis events or in aspartate aminotransferase and alanine aminotransferase levels were observed. CONCLUSIONS:: Lycopene and resveratrol pretreatment did not interfere on hepatic hyperplasia in partially hepatectomized rats.
Assuntos
Antioxidantes/farmacologia , Carotenoides/farmacologia , Hepatectomia/métodos , Fígado/efeitos dos fármacos , Fígado/cirurgia , Estilbenos/farmacologia , Alanina Transaminase/sangue , Animais , Apoptose/efeitos dos fármacos , Aspartato Aminotransferases/sangue , Fígado/enzimologia , Fígado/patologia , Regeneração Hepática/efeitos dos fármacos , Licopeno , Masculino , Índice Mitótico , Estresse Oxidativo/efeitos dos fármacos , Ratos Wistar , Reprodutibilidade dos Testes , Resveratrol , Fatores de Tempo , Resultado do TratamentoRESUMO
Purpose: To investigate the effects of lycopene and resveratrol pretreatment on hepatic hyperplasia in partially hepatectomized rats. Methods: The lycopene group and the resveratrol group received 40 mg/kg/day of lycopene or resveratrol, respectively (dissolved in olive oil or in saline solution, respectively) and administered via a gastric tube for 30 days. The partially hepatectomzed (PH) control groups received saline or olive oil via a gastric tube for 30 days, respectively, and the normal control group received no treatment. Liver tissue and intracardiac blood samples were obtained 24, 36 or 48 h after PH. Results: No areas of fibrosis were detected. No significant changes in mitotic index, in the number of apoptosis events or in aspartate aminotransferase and alanine aminotransferase levels were observed. Conclusions: Lycopene and resveratrol pretreatment did not interfere on hepatic hyperplasia in partially hepatectomized rats.(AU)
Assuntos
Animais , Masculino , Ratos , Alanina Transaminase , Hepatectomia , Aspartato Aminotransferases , Apoptose , Índice Mitótico , Carotenoides/uso terapêutico , Polifenóis/uso terapêutico , Fígado/irrigação sanguínea , Fígado/lesões , Fígado/cirurgiaRESUMO
Abstract Purpose: To investigate the effects of lycopene and resveratrol pretreatment on hepatic hyperplasia in partially hepatectomized rats. Methods: The lycopene group and the resveratrol group received 40 mg/kg/day of lycopene or resveratrol, respectively (dissolved in olive oil or in saline solution, respectively) and administered via a gastric tube for 30 days. The partially hepatectomzed (PH) control groups received saline or olive oil via a gastric tube for 30 days, respectively, and the normal control group received no treatment. Liver tissue and intracardiac blood samples were obtained 24, 36 or 48 h after PH. Results: No areas of fibrosis were detected. No significant changes in mitotic index, in the number of apoptosis events or in aspartate aminotransferase and alanine aminotransferase levels were observed. Conclusions: Lycopene and resveratrol pretreatment did not interfere on hepatic hyperplasia in partially hepatectomized rats.
Assuntos
Animais , Masculino , Estilbenos/farmacologia , Carotenoides/farmacologia , Hepatectomia/métodos , Fígado/cirurgia , Fígado/efeitos dos fármacos , Antioxidantes/farmacologia , Aspartato Aminotransferases/sangue , Fatores de Tempo , Reprodutibilidade dos Testes , Resultado do Tratamento , Ratos Wistar , Apoptose/efeitos dos fármacos , Estresse Oxidativo/efeitos dos fármacos , Alanina Transaminase/sangue , Fígado/enzimologia , Fígado/patologia , Regeneração Hepática/efeitos dos fármacos , Índice MitóticoRESUMO
ABSTRACT Quercetin has potent antioxidant action and a hepatoprotective role. The aim of this study was to evaluate the hepatoprotective action of quercetin pretreatment in paracetamol-induced liver damage (PILD) and structural injury resulting from partial hepatectomy (PH). In the first model, Wistar rats received oral quercetin (50mg/kg/day) during 8 days. On the 8th day, 3g/kg paracetamol were added. In the second model, the same quercetin dose was given during 7 days and rats were submitted to PH on the 8th day. Blood samples were obtained for determination of enzyme levels. Liver, heart, kidney and lung tissue were also collected for assessment of quercetin biodistribution and/or histological analyses. The results obtained after PILD were more pronounced at 24 hours, as reflected by the reduction of serum ALT levels and by the lower concentration of quercetin in liver at this time point. Quercetin also had a protective effect in groups submitted to PH, as shown by decreased ALT levels after 18 hours, and of AST levels after 18 and 36h. The reduction in serum AST and ALT levels suggest that treatment with quercetin is useful as a preoperative pharmacologic measure and for prevention of liver damage caused by drugs.